Why “the science speaks for itself” is the most expensive myth in biotech
Scientific Fluency
Jul 8, 2026
We once visited a biotech with a full wet lab, a serious dry lab, and hundreds of thousands of dollars of equipment. The scientists were excellent and the data was real. They could not raise.
Not because the science was weak. Because no one could translate it, quickly and clearly, into something an investor could believe. “The science speaks for itself” is the most expensive belief in biotech, because it quietly assumes the listener will do the interpretive work for you. They will not. And great science, poorly communicated, looks identical to mediocre science, poorly communicated.
Where the myth comes from, and why it feels true
The belief is not naive. It is an instinct trained into good scientists. In a paper, in peer review, the data really is supposed to win on its merits, and dressing it up is rightly suspect. Letting the work speak is a virtue in that room.
The mistake is carrying that instinct into a different room. An investor or partner meeting is not peer review. The people across the table are not evaluating whether your result is correct so much as whether they understand what you are building, why it matters, and why now. Confusing the two is a category error, and it is the root of the myth.
Investors meet the story before they meet the science
An investor reviewing a stack of opportunities forms a verdict on clarity within minutes. If the story does not land, the science never gets a fair hearing. Not because the work is not good, but because no one gave it a frame they could hold.
Great science, poorly communicated, looks the same as mediocre science, poorly communicated. The companies that raise are the ones where the listener walks out thinking: these people know exactly what they’re building and why it matters.
And the bar for being understood quickly is rising. Capital has turned selective. In 2025, the early-stage share of biopharma VC fell to 32%, down from over 40% in the pandemic years, with money flowing to fewer, better-articulated bets.
J.P. Morgan reported heightened diligence standards and longer decision timelines for early-stage startups. The companies that get through are the ones that make the case clearly, not the ones that assume it makes itself. As one veteran investor’s twenty-year retrospective puts it, the business case has to be made, not presumed.
The bill for the myth
Believing the science speaks for itself is not free. It shows up as:
A slower raise, or no raise. In a selective market, “interesting, but I didn’t quite get it” is a polite pass.
Lost second meetings. The science gets you in the room. An unclear narrative loses the room, quietly, in the follow-up that never comes.
The same words as ten competitors. When you do not translate what is distinctive, real differentiation becomes invisible. (More on that in why generic messaging is killing your pipeline.)
It’s not a science problem. It’s a communication problem.
Translation is not dumbing down. Done well, it makes the work legible without making it less true. It is comprehension, not reduction. The goal is for a smart listener to grasp what you have built and why it is hard to replicate, with the rigor intact.
What translating the science actually means
Translation is a discipline, not a vibe. Four moves do most of the work.
Open with the problem, not the modality. Lead with the stakes and who carries them. Your science is the answer, the second sentence, not the first.
Make the MoA or technology followable in one breath. If a smart non-specialist cannot repeat back how it works after one pass, the explanation is too complex, not the audience.
Turn the data into one throughline. Not every result, just the line they add up to. A figure should advance the argument, not only prove you did the work.
Answer “why you, why now” in a sentence. Why this team, this approach, this moment. If you cannot, the investor fills the gap with doubt.
None of this asks you to overstate the work. It asks you to make the work understandable to the people who control your funding and your partnerships, the same people who will judge the website and deck carrying that story long before they read a data point.
The translation is the strategy
The companies that raise are not always the ones with the best science. They are the ones where the science is understood. That capability, scientific fluency joined to narrative, is not a finishing touch on the real work. In a selective market, it is the work, and it is what we do. You can see it in the outcomes that followed clearer positioning, from a pitch-competition win to a $481M partnership.
If you suspect your story is not doing your science justice, find out before you go out. Apply for Signal for an honest, external read on where the story breaks down.
Sources
PitchBook 2025 biopharma VC analysis, via BioSpace: Early-Stage Biotechs Suffer in 2025
J.P. Morgan early-stage analysis, via BioSpace: Funding Favors Derisked Assets
LifeSciVC (Bruce Booth, Oct 2025): Twenty Years in Early-Stage Biotech VC, Part 3